Cilofexor (formerly GS-9674), a small-molecule non-steroidal agonist of FXR, significantly reduced hepatic steatosis, liver biochemical marker, and serum bile acid levels, but did not improve liver fibrosis or stiffness after 24 weeks of treatment (NCT02854605) (76). Here, NR1H4 is linked to Hepatic steatosis.